Trontinemab

Trontinemab
Monoclonal antibody
Type	?
Clinical data
Other names	RG6102
Legal status
Legal status	Investigational;
Identifiers
CAS Number	2568868-35-7;
UNII	N0GBZ1GWC2;

Trontinemab (RG6102) is a monoclonal antibody developed by Genentech based on gantenerumab, an anti-amyloid monoclonal antibody. Compared to gantenerumab, it has 50 times as much penetrance into the brain.^[1]^[2]^[3]^[4]

References[edit]

^ Steenhuysen, Julie (2022-12-01). "Roche shutters most trials of Alzheimer's drug after failed trials". Reuters. Retrieved 2023-11-26.
^ Zhang, Yun; Chen, Huaqiu; Li, Ran; Sterling, Keenan; Song, Weihong (30 June 2023). "Amyloid β-based therapy for Alzheimer's disease: challenges, successes and future". Signal Transduction and Targeted Therapy. 8 (1): 248. doi:10.1038/s41392-023-01484-7. ISSN 2059-3635. PMC 10310781. PMID 37386015.
^ Grimm, Hans Peter; Schumacher, Vanessa; Schäfer, Martin; Imhof-Jung, Sabine; Freskgård, Per-Ola; Brady, Kevin; Hofmann, Carsten; Rüger, Petra; Schlothauer, Tilman; Göpfert, Ulrich; Hartl, Maximilian; Rottach, Sylvia; Zwick, Adrian; Seger, Shanon; Neff, Rachel; Niewoehner, Jens; Janssen, Niels (2023). "Delivery of the Brainshuttle™ amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans". mAbs. 15 (1): 2261509. doi:10.1080/19420862.2023.2261509. ISSN 1942-0870. PMC 10572082. PMID 37823690.
^ Kulic, Luka; Vogt, Annamarie; Alcaraz, Fabien; Barrington, Philip; Marchesi, Maddalena; Klein, Gregory; Croney, Ruth; Agnew, David; Abrantes, João A.; Svoboda, Hanno (1 September 2022). "053 Brainshuttle AD: Investigating safety, tolerability, and PK/PD of RG6102 in prodromal/mild-to-moderate AD". Journal of Neurology, Neurosurgery & Psychiatry. 93 (9): e2. doi:10.1136/jnnp-2022-abn2.97. ISSN 0022-3050. S2CID 251518048.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[Steenhuysen_2022_w233-1] Steenhuysen, Julie (2022-12-01). "Roche shutters most trials of Alzheimer's drug after failed trials". Reuters. Retrieved 2023-11-26.

[2] Zhang, Yun; Chen, Huaqiu; Li, Ran; Sterling, Keenan; Song, Weihong (30 June 2023). "Amyloid β-based therapy for Alzheimer's disease: challenges, successes and future". Signal Transduction and Targeted Therapy. 8 (1): 248. doi:10.1038/s41392-023-01484-7. ISSN 2059-3635. PMC 10310781. PMID 37386015.

[3] Grimm, Hans Peter; Schumacher, Vanessa; Schäfer, Martin; Imhof-Jung, Sabine; Freskgård, Per-Ola; Brady, Kevin; Hofmann, Carsten; Rüger, Petra; Schlothauer, Tilman; Göpfert, Ulrich; Hartl, Maximilian; Rottach, Sylvia; Zwick, Adrian; Seger, Shanon; Neff, Rachel; Niewoehner, Jens; Janssen, Niels (2023). "Delivery of the Brainshuttle™ amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans". mAbs. 15 (1): 2261509. doi:10.1080/19420862.2023.2261509. ISSN 1942-0870. PMC 10572082. PMID 37823690.

[4] Kulic, Luka; Vogt, Annamarie; Alcaraz, Fabien; Barrington, Philip; Marchesi, Maddalena; Klein, Gregory; Croney, Ruth; Agnew, David; Abrantes, João A.; Svoboda, Hanno (1 September 2022). "053 Brainshuttle AD: Investigating safety, tolerability, and PK/PD of RG6102 in prodromal/mild-to-moderate AD". Journal of Neurology, Neurosurgery & Psychiatry. 93 (9): e2. doi:10.1136/jnnp-2022-abn2.97. ISSN 0022-3050. S2CID 251518048.

[1]

[2]

[3]

[4]